Water treatment systems designed to remove the toxic “forever chemicals” known as PFAS may provide far greater public health benefits than previously recognized, according to new research from the ...

BARCELONA, Spain — A new phase 3 trial of ocrelizumab in primary progressive multiple sclerosis (PPMS) showed meaningful benefit in older patients and those with advanced disease — a first for this ...

Opdivo plus AVD showed superior PFS and EFS compared to Adcetris plus AVD in patients with advanced Hodgkin lymphoma. The Opdivo regimen had a better side effect profile, with fewer severe side ...

Gleevec remains effective in advanced GIST, with median overall survival of 75.3 months and significant long-term survival rates. Factors like female sex, gastric tumor location, smaller tumors, and ...

A changing workplace, economic factors and an expanded array of options are among the issues influencing the employee benefits landscape in 2024, according to LIMRA research. Patrick Leary, LIMRA ...